NCT06147960 Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
| NCT ID | NCT06147960 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nīmes |
| Condition | Cancer of Cervix |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-09-26 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2024-09-26 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.
Eligibility Criteria
Inclusion Criteria: * Patients treated with the exclusive radio-chemotherapy combination for locally advanced cervical carcinoma (stage Ib-IVb according to FIGO classification). * Patients aged ≥ 18 years. * Patients with a minimum of 2 years post-treatment follow-up. * Patients for whom the initial biopsy specimen (before treatment) is available. * Patients who have not indicated that they do not wish to participate in the study. * Patients affiliated to or benefiting from a health insurance scheme. Exclusion Criteria: * Patients under court protection, guardianship or curatorship.
Contact & Investigator
Alexandre TAYART de BORMS, Interne
PRINCIPAL INVESTIGATOR
Nîmes University Hospital
Frequently Asked Questions
Who can join the NCT06147960 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Cancer of Cervix. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06147960 currently recruiting?
Yes, NCT06147960 is actively recruiting participants. Contact the research team at frederic.fiteni@chu-nimes.fr for enrollment information.
Where is the NCT06147960 trial being conducted?
This trial is being conducted at Nîmes, France.
Who is sponsoring the NCT06147960 clinical trial?
NCT06147960 is sponsored by Centre Hospitalier Universitaire de Nīmes. The principal investigator is Alexandre TAYART de BORMS, Interne at Nîmes University Hospital. The trial plans to enroll 180 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.